Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

Sponsor
The Second Affiliated Hospital of Shandong First Medical University
Study ID
NCT05184946
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab Combined with SOX — DRUG
    Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma

Study Details

To study the efficacy and safety of camrelizumab combined with SOX regimen for adjuvant therapy of stage III gastric cancer

Key Dates

Start date
Oct 9, 2021
Status verified
Dec 2021
Primary completion
Oct 8, 2025
Completion
Oct 8, 2025

Study Design

Enrollment
72 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Anti-PD1 combined with SOX
    Camrelizumab will be administered one day before SOX regimen.

Primary Outcome Measure

3 years disease free survival rate [ Time Frame: 3 years ]

Central Contacts

Related Studies